文献速递类风湿关节炎

类风湿关节炎不同药物治疗组间淋巴瘤亚型谱:欧洲登记协作项目

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.
PubMed 文献 · Ann Rheum Dis · 2017-08-19

该研究基于12个欧洲生物制剂登记库,前瞻性随访124 997例类风湿关节炎患者,共报告533例淋巴瘤。患者淋巴瘤亚型分布与一般人群不同(DLBCL更多、CLL更少),但从未暴露于bDMARD者与TNFi治疗者之间亚型分布相似。

要点

  • RA患者淋巴瘤以B细胞NHL为主,DLBCL占B细胞NHL的55.8%。
  • 与一般人群相比,RA患者DLBCL更多、慢性淋巴细胞白血病更少。
  • TNFi治疗者与bionaïve者的淋巴瘤亚型分布无差异证据。

核心结论

  • RA患者淋巴瘤亚型分布与一般人群不同,但TNFi治疗未改变亚型分布。

研究设计与样本

  • 来自12个欧洲生物制剂登记库的前瞻性队列,纳入124 997例RA患者(平均年龄59岁,女性73.7%)。
  • 患者分为从未暴露于bDMARD(bionaïve)和曾接受bDMARD治疗两组,随访首次组织学确诊淋巴瘤。
  • 淋巴瘤归因于最近一次接受的bDMARD。

主要发现

  • 共报告533例淋巴瘤,其中HL占9.5%,B细胞NHL占83.8%,T细胞NHL占6.8%。
  • 未观察到肝脾T细胞淋巴瘤病例。
  • DLBCL是最常见的B细胞NHL亚型,占所有B细胞NHL的55.8%。
  • bionaïve患者与TNFi治疗者的淋巴瘤亚型分布相似。
  • 其他bDMARDs病例数过少,无法得出结论。

关键数值与推荐

  • RA患者与一般人群相比,DLBCL更多、慢性淋巴细胞白血病更少。

临床怎么用

  • TNFi治疗RA时,淋巴瘤亚型分布与未暴露bDMARD者相似,无需因特定亚型风险改变TNFi使用策略。

局限性

  • 其他bDMARDs(非TNFi)的淋巴瘤病例数过少,无法评估其亚型分布影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma. Patients were considered exposed to a bDMARD after having received the first dose. Lymphomas were attributed to the most recently received bDMARD. RESULTS: Among 124 997 patients (mean age 59 years; 73.7% female), 533 lymphomas were reported. Of these, 9.5% were HL, 83.8% B-cell NHL and 6.8% T-cell NHL. No cases of hepatosplenic T-cell lymphoma were observed. Diffuse large B-cell lymphoma (DLBCL) was the most frequent B-cell NHL subtype (55.8% of all B-cell NHLs). The subtype distributions were similar between bionaïve patients and those treated with tumour necrosis factor inhibitors (TNFi). For other bDMARDs, the numbers of cases were too small to draw any conclusions. Patients with RA developed more DLBCLs and less chronic lymphocytic leukaemia compared with the general population. CONCLUSION: This large collaborative analysis of European registries has successfully collated subtype information on 533 lymphomas. While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mercer LK, Regierer AC, Mariette X, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017. PMID: 28822981. doi:10.1136/annrheumdis-2017-211623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。